MAZE (Maze Therapeutics) Short Interest


MAZE Maze Therapeutics Inc MAZE
14 GF Score
Price $27.02
! 2 Warning Signs
View Full Analysis

What is Maze Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MAZE vs FTRE, ARDX, MBX: Short Interest Comparison

For the Biotechnology subindustry, Maze Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maze Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maze Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Maze Therapeutics's Short Interest falls into.


MAZE
14GF Score
Maze Therapeutics Inc MAZE
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maze Therapeutics Business Description

Address 171 Oyster Point boulevard, Suite 300, South San Francisco, CA, USA, 94080
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
14GF Score

Get the complete analysis for MAZE

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.02
Price